Tianjin Medical University General Hospital is a general hospital in the central Heping District of the Chinese metropolis of Tianjin, associated with Tianjin Medical University.

During the past decade, Tianjin Medical University General Hospital conducted 224 clinical trials. In the 10-year time frame, 224 clinical trials started and 34 clinical trials were completed, i.e. on average, 15.2% percent of trials that started reached the finish line to date. In the past 5 years, 148 clinical trials started and 28 clinical trials were completed. i.e. 18.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tianjin Medical University General Hospital" #1 sponsor was "Tianjin Medical University General Hospital" with 23 trials, followed by "Eli Lilly and Company" with 16 trials sponsored, "Hoffmann-La Roche" with 13 trials sponsored, "Janssen Research & Development, LLC" with 13 trials sponsored and "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 13 trials sponsored. Other sponsors include 170 different institutions and companies that sponsored additional 119 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tianjin Medical University General Hospital" #1 collaborator was "Tianjin Medical University General Hospital" with 16 trials as a collaborator, "The Second Hospital of Hebei Medical University" with 6 trials as a collaborator, "Peking Union Medical College Hospital" with 5 trials as a collaborator, "First Affiliated Hospital Xi'an Jiaotong University" with 4 trials as a collaborator and "Guangdong Provincial People's Hospital" with 4 trials as a collaborator. Other collaborators include 235 different institutions and companies that were collaborators in the rest 193 trials.

According to Clinical.Site data, the most researched conditions in "Tianjin Medical University General Hospital" are "Multiple Myeloma" (6 trials), "Carcinoma, Non-Small-Cell Lung" (5 trials), "Non-Small Cell Lung Cancer" (5 trials), "Stroke" (5 trials) and "Systemic Lupus Erythematosus" (5 trials). Many other conditions were trialed in "Tianjin Medical University General Hospital" in a lesser frequency.

Most popular intervention types in "Tianjin Medical University General Hospital" are "Drug" (192 trials), "Device" (26 trials), "Other" (11 trials), "Biological" (10 trials) and "Diagnostic Test" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (58 trials), "Carboplatin" (9 trials), "Tislelizumab" (8 trials), "Pemetrexed" (6 trials) and "Cisplatin" (5 trials). Other intervention names were less common.

The vast majority of trials in "Tianjin Medical University General Hospital" are 237 trials for "All" genders, 12 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Tianjin Medical University General Hospital". 8 are not yet recruiting, 76 are recruiting, 37 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 80 completed trials in Tianjin Medical University General Hospital, 1 suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Tianjin Medical University General Hospital, 15 "Phase 1" clinical trials were conducted, 59 "Phase 2" clinical trials and 113 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 15 trials, and there were also 40 trials that are defined as “Not Applicable".

Tianjin Medical University General Hospital has several departments that took part in Clinical trials: "Department of Radiology, the Affiliated Drum Tower Hospital of Nanjing University" - 3 trials